1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMyasthenia Gravis Premium and Copay Program is sponsored by National Organization for Rare Disorders (NORD). NORD's program assists eligible individuals who have health insurance with funding to cover health insurance premiums, deductibles, copayments, and coinsurance costs associated with the care of Myasthenia Gravis.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NORD Launches Financial Assistance Programs for MG Patients in US NORD Launches Financial Assistance Programs for MG Patients in US Preferred Source on Google The National Organization for Rare Disorders (NORD), a nonprofit organization dedicated to supporting those with rare diseases, has launched new patient assistance programs for people with myasthenia gravis (MG) living in the U.S. The new assistance programs aim to help patients who have limited financial resources with out-of-pocket healthcare expenses, such as health insurance deductibles and copayments.
Patients also can receive financial assistance to help cover the costs of medical appointments, prescribed medications and tests, and forms of rehabilitation therapy. At the moment, NORD is offering two types of assistance programs for those with MG: a premium and copay program, and a medical assist program. The premium and copay program is intended for MG patients who have health insurance.
It seeks to provide financial support to help these individuals cover the costs of health insurance premiums, deductibles, copays, and coinsurance costs related to MG. In contrast, the medical assist program is intended for those who do not have health insurance, or for those for whom medical coverage has been refused.
In addition to providing financial assistance with medical appointment costs, prescribed MG therapies, and lab or diagnostic tests, this program may cover mileage and travel expenses for MG-related medical appointments. Both programs are open to U.S. citizens and those living in the country for at least six months, who can provide a proof of residency, such as a utility bill with their name and home address.
Eligible applicants need to have a confirmed diagnosis of MG. In addition to meeting these criteria, applicants must show financial eligibility, which will be verified by a RareCare patient services representative through an electronic income verification, or EIV system. A RareCare representative will guide applicants through the process.
Patients who do not initially meet the criteria for support will be sent an application and disclosure forms by e-mail, fax, or mail. The applicant then can provide the appropriate financial documentation to verify need, and return the forms to NORD for further evaluation. Program awards are granted on a first come, first served basis, and are valid for an entire calendar year.
Those requiring continuous financial assistance are encouraged to reapply. Once accepted into one of the two programs, patients will be eligible to receive reimbursements for their medical expenses, or have them prepaid by NORD. Importantly, all claims must be submitted within 30 days following the service and be accompanied by a receipt or proof of payment.
After receiving all information, NORD will issue a reimbursement within 10 business days. In addition to MG, NORD is currently offering patient assistance programs for other rare diseases. A complete list of the programs being offered by the nonprofit can be found here .
Preferred Source on Google Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology, and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns.
In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France. She has also authored several research papers published in peer-reviewed international scientific journals. Joana joined Bionews in 2018, starting as a science writer, then moving to a science editor position in 2020, and to editorial associate director of resource pages in 2025.
advocacy Charity Cost of treatment Fill in the required fields to post. Your email address will not be published.
Scholarship success stories inspire new round of MG applications Health insurance and financial assistance for myasthenia gravis Myasthenia gravis support groups and resources UCB launches US scholarship program for MG patients, families IVIgs, immunosuppressants add up to higher MG healthcare costs in US Scholarship success stories inspire new round of MG applications Health insurance and financial assistance for myasthenia gravis Myasthenia gravis support groups and resources Get regular updates to your inbox.
This field is for validation purposes and should be left unchanged. [wppb-login register_url="/register" lostpassword_url="/recover-password" ajax=true] Create your account by filling in the information below: [wppb-register redirect_url="/welcome" ajax=true] < Back to registration options [wppb-recover-password ajax=true]
According to the current listing, eligibility includes: United States citizens or U. S. residents of six (6) months or greater with evidence of residency, who are diagnosed with Myasthenia Gravis and meet medical and financial needs criteria. Confirm the full requirements in the official notice before applying.
Myasthenia Gravis Premium and Copay Program is funded by National Organization for Rare Disorders (NORD). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Anthropic is giving rare-disease researchers and early-stage biotechs up to $50,000 in Claude API credits over six months — not cash, but compute. Here is how the two-track program works, who is eligible, what the credits can and cannot do, and how it fits a fast-growing new category: the compute-as-grant model reshaping how AI-for-science actually gets funded.
Read articleThe Department of Energy's Office of Critical Minerals and Energy Innovation is spending to break America's 95% dependence on foreign rare earths. The strategy is unusual: recover critical materials from the waste streams of coal plants, smelters, and refineries that already exist. Here is the full funding architecture — the $75M just awarded, the $500M battery-materials round, the $1B pipeline behind them — and how an industrial operator should position for what comes next.
Read articleOn June 2, 2026, the Department of Energy's Office of Critical Minerals and Energy Innovation selected two demonstration-scale facilities — Phoenix Tailings (with MIT and the University of Minnesota) for $66 million, and the Colorado School of Mines (with ElementUSA, PNNL, Principal Mineral, and Rare Earth Technologies Inc.) for the balance — under the Rare Earth Elements Demonstration Facility Program. Both projects pull rare earths from industrial waste — red mud at the Gramercy refinery in Louisiana, and a mix of mine and refining tailings elsewhere. Here is what the selections tell researchers, small businesses, and downstream magnet customers about where DOE thinks the chokepoint actually is, and what to do before the next demonstration-scale solicitation opens.
Read article